10月12日 - 医疗设备制造商斯特利斯将以21亿美元收购私营公司Xodus Medical，将旨在提高患者和手术室工作人员安全性的手术产品加入其医疗耗材业务。
Oct 12 - Medical equipment maker Steris will buy privately held Xodus Medical for $2.1 billion, adding surgical products designed to improve safety for patients and operating-room staff to its healthcare consumables business.
此次收购加强了斯特利斯进军医院和实验室的步伐，其灭菌和耗材业务在这些领域已看到持续需求。
The acquisition strengthens Steris' push into hospitals and laboratories, where its sterilization and consumables business is already seeing sustained demand.
8月，作为其耗材推进计划的一部分，该公司表示将投资6亿美元在北卡罗来纳州建设一个中心，用于生产和分销用于医疗灭菌和药品生产的配方化学品。
In August, as part of its consumables push, the company said it would spend $600 million on a North Carolina hub to manufacture and distribute formulated chemicals used in healthcare sterilization and pharmaceutical production.
“总体而言，这是一次合乎逻辑的收并购，为斯特利斯的医疗业务增加了额外的手术室用品，” 斯蒂芬斯分析师Steven Etoch表示。
"Net-net, this is a logical tuck-in that adds additional operating-room supplies to Steris' healthcare business," said Stephens analyst Steven Etoch.
他还表示，斯特利斯可能通过利用其更大的销售网络以及与医院手术室的既有关系来提升Xodus的销售额。
He also said Steris may be able to lift Xodus sales by using its larger sales network and established relationships with hospital operating rooms.
Xodus为全球医院制造手术安全设备，最知名的是其Pink Pad系统，该系统可固定和稳定手术台上的患者，以降低手术过程中滑倒或因压力导致受伤的风险。
Xodus makes surgical-safety devices for hospitals worldwide and is best known for its Pink Pad system, which secures and stabilizes patients on the operating table to reduce the risk of slipping or pressure-related injury during surgery.
其产品组合还包括一次性手术室产品，如电外科配件、药品标签、手术镜片防雾产品以及用于处理针头和其他锐利手术器械的安全装置。
Its portfolio also includes single-use operating-room products such as electrosurgical accessories, medication labels, anti-fog products for surgical lenses, and safety devices for the handling of needles and other sharp surgical instruments.
斯特利斯计划主要通过债务融资收购Xodus Medical，该交易预计将在2026年12月31日前完成，需获得监管批准。
Steris plans to fund the Xodus Medical acquisition primarily with debt, with the transaction expected to close by December 31, 2026, subject to regulatory approvals.
公司预计该交易将产生净现值约3亿美元的现金税收益，从而使净购买价约为18亿美元。
The company expects the deal will generate cash tax benefits with a net present value of about $300 million, resulting in a net purchase price of about $1.8 billion.
斯特利斯表示，总部位于宾夕法尼亚州的Xodus Medical预计将在2026年创造约2.45亿美元的收入。
Steris said Pennsylvania-based Xodus Medical is anticipated to generate about $245 million in revenue in 2026.